| Trial ID: | L0145 |
| Source ID: | NCT04845646
|
| Associated Drug: |
Itraconazole
|
| Title: |
DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.
|
| Acronym: |
--
|
| Status: |
Completed
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Healthy|NAFLD
|
| Interventions: |
Drug: ASC41|Drug: Itraconazole|Drug: Phenytoin
|
| Outcome Measures: |
AUC of ASC41|Cmax of ASC41|t1/2 of ASC41|CL/F of ASC41|Vd/F of ASC41|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
|
| Sponsor/Collaborators: |
Gannex Pharma Co., Ltd.
|
| Gender: |
All
|
| Age: |
18 Years to 65 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 1
|
| Enrollment: |
24
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
|
| Start Date: |
March 16, 2021
|
| Completion Date: |
June 10, 2021
|
| Results First Posted: |
--
|
| Last Update Posted: |
July 19, 2021
|
| Locations: |
ICON early Phase Services LLC, San Antonio, Texas, United States
|
| URL: |
https://ClinicalTrials.gov/show/NCT04845646
|
